Cabaletta Bio, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
CABA$1.45-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(94,533) | $(81,071) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 10,755 | 10,866 |
| Depreciation | 708 | 953 |
| Non-cash finance lease expense | 7,023 | 4,884 |
| Non-cash operating lease expense | 1,962 | 1,787 |
| Accretion of operating lease liabilities | 177 | 309 |
| Amortization of discount on investments | (368) | (35) |
| Loss on foreign currency exchange rates | 103 | 61 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (658) | (1,012) |
| Other assets | (1,048) | (209) |
| Accounts payable | (1,177) | 2,186 |
| Accrued and other current liabilities | (4,684) | 2,067 |
| Lease liabilities | (2,114) | (2,114) |
| Accrued interest payable under finance lease | (221) | 100 |
| Net cash used in operating activities | (84,075) | (61,228) |
| Cash flows from investing activities: | ||
| Proceeds from maturities of investments | 50,960 | — |
| Purchases of investments | — | (49,035) |
| Purchases of property and equipment | — | (946) |
| Net cash provided by (used in) investing activities | 50,960 | (49,981) |
| Cash flows from financing activities: | ||
| Issuance of common stock, net of issuance costs of $9,801 | 140,201 | — |
| Issuance of common stock from ATM offering, net of sales agent commission and fees | 28,730 | 2,595 |
| Proceeds from issuance of common stock upon exercise of common stock warrants | 13,188 | — |
| Proceeds from the issuance of common stock, warrants and pre-funded warrants, net of issuance costs | — | 93,583 |
| Proceeds from issuance of common stock in connection with theexercise of stock options | 66 | — |
| Proceeds from issuance of common stock under employee stock purchase plan | 160 | 197 |
| Principal payments on finance leases | (7,091) | (3,554) |
| Net cash provided by financing activities | 175,254 | 92,821 |
| Effect of exchange rate changes on cash and cash equivalents | (20) | 38 |
| Net increase (decrease) in cash and cash equivalents | 142,119 | (18,350) |
| Cash and cash equivalents—beginning of period | 82,982 | 163,962 |
| Cash and cash equivalents—end of period | $225,101 | $145,612 |
| Supplemental disclosures | ||
| Cash paid for interest | $1,374 | $765 |
| Property and equipment purchases included in accounts payable and accrued expenses | $265 | $43 |
| Offering costs included in accounts payable and accrued expenses | $— | $25 |
| Right-of-use assets obtained in exchange for finance lease obligations | $4,046 | $14,934 |
| Right-of-use assets obtained in exchange for operating lease obligations | $4,213 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.